Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
US-Approved Neupogen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Filgrastim Hospira | EXPERIMENTAL | - |
| US-Approved Neupogen | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Filgrastim Hospira | BIOLOGICAL | 5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2. |
| US-Approved Neupogen | BIOLOGICAL | 5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2. |
Inclusion Criteria: 1. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. 2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. Healt...
Neupogen is used for neutropenia, a condition of low white blood cell count. It is also studied in healthy volunteers to assess immune response and pharmacokinetics. The drug is a monoclonal antibody developed by Pfizer, Inc. (PFE) and is currently in Phase 1 clinical development.
Neupogen is developed by Pfizer, Inc., which trades under the ticker PFE. The drug is a monoclonal antibody being studied for neutropenia and in healthy volunteers. It is currently in Phase 1 clinical trials.
Neupogen is in Phase 1 clinical development. It has completed two Phase 1 trials, with no active trials currently ongoing. The drug is investigational and not yet approved for any indication.
Neupogen has been studied in three completed Phase 1 trials: NCT02766634, NCT02766647, and NCT02923791. These trials evaluated the drug in healthy volunteers and in subjects with neutropenia, with total enrollment of 256 participants across all studies.
Neupogen is used as a reference product in trials comparing it to Filgrastim Hospira. The trials NCT02766634 and NCT02766647 test Filgrastim Hospira against the already U.S.-approved Neupogen, while NCT02923791 assesses immune response to both products.